The headline reads as positive (95% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › LFST
Lifestance Health Group, Inc. (LFST) stock analysis
WEAK BUY 26% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Lifestance Health Group, Inc. (LFST) WEAK BUY with 26% confidence at a price of $13.33. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$13.33
Technical picture
The 14-day RSI is 66, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.0x its 20-day average; light trading makes the latest move less convincing.
Fundamentals
The company reports a profit margin of 3.2% and revenue growth of +26.1%.
In its latest quarter it earned $0.11 per share, which beat the $0.08 analysts expected, with revenue +26.1% year over year.
Wall Street's average rating is 1.5 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $14.45.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $13.33, a target of $14.11 (+5.9%) and a stop-loss at $12.53 (-6.0%).
That is a reward-to-risk ratio of about 1.0 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 4, 2026 whatever the price does.
Entry$13.33
Target$14.11
Stop-loss$12.53
Reassess byNov 4, 2026
Research notes
LFST’s bull case is accelerating operating performance: Q2 revenue rose 26% year over year, adjusted EBITDA increased 94%, visits grew 19%, and management raised its full-year outlook; analysts have also lifted targets as high as $15–$18. The bear case is valuation and execution risk: shares have surged roughly 168% over the past year, trade near a new 52-week high, and have been flagged as slightly above fair value, while the business remains sensitive to clinician capacity, utilization, payer relationships, and cash-flow conversion. The major recent catalyst was the strong Q2 report—$435.35 million revenue and $0.06 adjusted EPS versus expectations of $414.38 million and $0.03—which helped drive the rally. Near-term focus is the expected Q3 release on November 5, with consensus revenue of about $431.6 million and EPS of $0.04.
The model's one-paragraph read
Leans BUY — composite score +0.26 (WEAK BUY). Technicals: RSI 65.64, MACD bullish, price above SMA50. Fundamentals: margin 3.2%, revenue growth 26.1%. Financial results: YoY revenue +26.1%, last EPS surprise +37.5%, next earnings 2026-11-05. FinGPT news read: positive. Internet research: LFST’s **bull case** is accelerating operating performance: Q2 revenue rose 26% year over year, adjusted EBITDA increased 94%, visits grew 19%, and management raised its full-year outlook; analysts have also lifted targets as high as $15–$18. The **bear case** is valuation and execution risk: shares have surged roughly 168% over the past year, trade near a new 52-week high, and have been flagged as slightly above fair value, while the business remains sensitive to clinician capacity, utilization, payer relationships, and cash-flow conversion. The major recent catalyst was the strong Q2 report—$435.35 million revenue and $0.06 adjusted EPS versus expectations of $414.38 million and $0.03—which helped drive the rally. Near-term focus is the expected Q3 release on November 5, with consensus revenue of about $431.6 million and EPS of $0.04. Suggested levels: entry $13.33, target $14.11, stop-loss $12.53, exit by 2026-11-04 (exit before next earnings (2026-11-05) -- this signal doesn't price in that report).
Past ratings for LFST
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | WEAK BUY | 26% | $13.33 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on LFST
Oct 29, 2026 · LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows
- Oct 29, 2026: LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows (PR Newswire)
Frequently asked questions
Is LFST a buy right now?
As of Oct 29, 2026, our automated model rates Lifestance Health Group, Inc. (LFST) WEAK BUY with 26% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for LFST?
The model's most recent plan targets $14.11 with a stop-loss at $12.53, from an entry near $13.33.
When does Lifestance Health Group, Inc. report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.